Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

被引:0
|
作者
Yilmaz, Mukaddes [1 ]
Basak, Mustafa [2 ]
Ozyukseler, Deniz Tataroglu [3 ]
Yildirim, Mahmut Emre [4 ]
Arik, Zafer [5 ]
Salman, Mehmet Coskun [6 ]
Gultekin, Murat [6 ]
Akgor, Utku [7 ]
Inci, Bediz Kurt [8 ]
Gurler, Fatih [9 ]
Yucel, Kadriye Bir [10 ]
Savas, Gozde [10 ]
Onan, Mehmet Anil
Sunar, Veli [12 ]
Meydanli, Mehmet Mutlu [11 ,13 ]
Yazici, Ozan
Ozet, Ahmet [10 ]
机构
[1] Sivas Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkiye
[2] Gazi Osman Pasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkiye
[3] Fethi Sekin State Hosp, Dept Med Oncol, Elazig, Turkiye
[4] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye
[6] Hacettepe Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[7] Ankara Numune Training & Res Hosp, Dept Gynecol Oncol, Ankara, Turkiye
[8] Kirsehir Training & Res Hosp, Dept Med Oncol, Kirsehir, Turkiye
[9] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Med Oncol, Ankara, Turkiye
[10] Gazi Univ, Dept Med Oncol, Fac Med, Ankara, Turkiye
[11] Gazi Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[12] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkiye
[13] Med Pk Hosp, Dept Gynecol Oncol, Gaziantep, Turkiye
关键词
Interval debulking; neoadjuvant chemotherapy; ovarian carcinoma; primary debulking; CANCER; SURVIVAL; CYTOREDUCTION; OUTCOMES;
D O I
10.5505/tjo.2023.3883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of the study is to compare treatment outcomes of the patients with federation of gynecology and obstetrics stages III and IV ovarian carcinomas, who underwent interval debulking surgery after neoadjuvant chemotherapy (NACT), and patients who underwent adjuvant chemotherapy after primary debulking surgery (PDS). METHODS Patients from four centers (n=183) were retrospectively evaluated. Of the patients, 91 (50%) were in the PDS group and 92 (50%) in the NACT group. RESULTS In the NACT group patients have advanced age, poor performance status, high levels of CA125, and advanced disease stage compared with the PDS group (p<0.050). Of the patients receiving NACT, 14 (15%) had a complete response, and 68 (74%) had a partial response. The R0 rate was higher in the PDS group (p=0.018). In univariate analysis, poor prognostic factors affecting OS were NACT in the treatment protocol (p<0.001), poor performance status (p<0.001), advanced age (<70 vs. >= 70, p=0.002), advanced clinical stage (p=0.042), and localization of the tumor with the largest diameter outside the omentum and ovary at the time of diagnosis (p=0.029). In the multivariate analysis, the presence of NACT (HR: 2.30, 95% CI: 1.25-4.23, p=0.007) and poor performance (HR: 2.52, 95% CI: 1.18-5.10, p=0.017) were independent poor prognostic factors for OS. CONCLUSION In the study, OS was better in the PDS group than in the NACT group. This result was thought to be associated with the NACT group having more disadvantageous characteristics (advanced age, poor performance, high CA125 level, advanced stage, etc.).
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [21] Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery
    Pepin, K. J.
    Davis, M. R.
    Bregar, A. J.
    Melamed, A.
    Hinchcliff, E. M.
    Gockley, A. A.
    del Carmen, M. G.
    Horowitz, N. S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 140 - 140
  • [22] Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer
    Morice, P
    Dubernard, G
    Rey, A
    Atallah, D
    Pautier, P
    Pomel, C
    Lhommé, C
    Duvillard, P
    Castaigne, D
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2003, 197 (06) : 955 - 963
  • [23] NEOADJUVANT CHEMOTHERAPY VERSUS PRIMARY DEBULKING SURGERY IN FIGO STAGE III AND IV EPITHELIAL OVARIAN, TUBAL OR PERITONEAL CANCER
    Tzanis, A.
    Iavazzo, C. R.
    Hadjivasilis, A.
    Tsouvali, H.
    Antoniou, G.
    Antoniou, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A296 - A296
  • [24] Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer Reply
    Edelson, Mitchell I.
    Wright, Alexi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 803 - 803
  • [25] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Shelly M. Seward
    Ira Winer
    Cancer and Metastasis Reviews, 2015, 34 : 5 - 10
  • [26] Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma
    Giannopoulos, T
    Butler-Manuel, S
    Taylor, A
    Ngeh, N
    Thomas, H
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2006, 27 (01) : 25 - 28
  • [27] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Seward, Shelly M.
    Winer, Ira
    CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 5 - 10
  • [28] Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer - a retrospective cohort study
    Maricic, Slobodan
    Mandic, Aljosa
    Dejanovic, Ninoslav
    Kladar, Nebojsa
    Popovic, Marina
    Ivkovic-Kapicl, Tatjana
    Gutic, Bojana
    Kokanov, Dunja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1193 - 1199
  • [29] Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
    Onda, Takashi
    Satoh, Toyomi
    Ogawa, Gakuto
    Saito, Toshiaki
    Kasamatsu, Takahiro
    Nakanishi, Toru
    Mizutani, Tomonori
    Takehara, Kazuhiro
    Okamoto, Aikou
    Ushijima, Kimio
    Kobayashi, Hiroaki
    Kawana, Kei
    Yokota, Harushige
    Takano, Masashi
    Kanao, Hiroyuki
    Watanabe, Yoh
    Yamamoto, Kaichiro
    Yaegashi, Nobuo
    Kamura, Toshiharu
    Yoshikawa, Hiroyuki
    EUROPEAN JOURNAL OF CANCER, 2020, 130 : 114 - 125
  • [30] Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients
    Vergote, I
    De Wever, I
    Tjalma, W
    Van Gramberen, M
    Decloedt, J
    van Dam, P
    GYNECOLOGIC ONCOLOGY, 1998, 71 (03) : 431 - 436